'FTC and FDA Risk: Where Peptide Marketing Crosses the Line'

You can sell a research-use-only peptide and stay inside the rules. You can also sell the exact same vial, change three sentences of marketing copy, and turn it into an unapproved drug in the eyes of the FDA and a deceptive health claim in the eyes of the FTC. The molecule never changed. Your legal posture did. This article maps the line peptide marketing crosses, shows how a crossed line cascades into a frozen merchant account, and lays out how to market within the RUO frame without giving up persuasion.

Two regulators, two different tripwires

Most peptide operators lump "the government" into one threat. It helps to separate the two agencies, because they police different things and a single piece of copy can trigger both.

The FDA cares about what a product is. Under the Federal Food, Drug, and Cosmetic Act, the agency decides drug status by "intended use." If you market a substance to diagnose, cure, mitigate, treat, or prevent a disease, or to affect the structure or function of the human body, the FDA can classify it as a drug regardless of what your label says. An unapproved drug sold to consumers is a textbook enforcement target. Intended use is inferred from your words: site copy, ads, social posts, customer-service replies, even your testimonials.

The FTC cares about whether your claims are truthful and substantiated. Its standard is competent and reliable scientific evidence behind any health or performance claim. A claim that a peptide produces a result, with no qualifying human trials to back it, is a deceptive-advertising violation on its face. The FTC has been aggressive on weight-loss and "miracle" health marketing for decades, and the incretin (GLP-1) gold rush put the whole adjacent category under a brighter light.

Here is the part that catches operators off guard: research-use-only labeling is your defense against the FDA's intended-use test, but only if your marketing honors it. The label says "not for human consumption." If your marketing says the opposite, regulators read the marketing, not the sticker. The sticker becomes evidence that you knew better.

How a marketing claim turns RUO into an unapproved drug

The RUO frame works because it removes human intended use from the picture. You are selling a compound to laboratories and researchers for study, not to people for ingestion. Drug status hinges on intended use, so when there is no human-use intent expressed anywhere, there is no drug to regulate as one.

Marketing is where that frame collapses. Each of the following moves injects human intended use back into your product and reclassifies it:

• Dosing language. "Take 250mcg twice weekly" is an instruction for human use. Researchers reconstitute and measure for experiments. They do not "take" anything. Dosing copy is the single fastest way to convert an RUO vial into an unapproved drug.
• Disease and condition claims. Tying a peptide to weight loss, healing, recovery, anti-aging, libido, or any human condition states intended use and triggers both agencies at once.
• Before-and-after photos and testimonials. A customer photo or a quote about results is a human-use claim made through someone else's mouth. It still counts as your claim.
• Route-of-administration cues. Pairing vials with syringes, injection guides, or "subcutaneous" instructions signals the product is meant to go into a body.
• Outcome promises and structure-function statements. "Boosts growth hormone," "burns fat," "repairs tissue." Each describes an effect on the human body, which is the FDA's structure-function trigger.
• Comparisons to prescription medicines. Positioning a research compound as a cheaper alternative to a named prescription medication implies the same human use and invites the comparison no operator wants.

None of these requires bad intent. A founder copying competitor copy, a contractor writing "punchy" product descriptions, or an affiliate freelancing on claims can each move your catalog across the line without you noticing. For the labeling discipline that has to sit underneath all of this, read ./ruo-labeling-compliance.md.

The cascade: from a claim to a frozen account

Operators tend to think of FTC and FDA risk as a slow, government-paced threat: maybe a warning letter someday. The faster, more common consequence runs through your payment processor, and it moves in days, not years.

Card networks and acquiring banks treat unapproved-drug and deceptive-health-claim exposure as a brand-risk and legal-risk problem they own. Your processor does not wait for an FDA letter. It runs its own monitoring, fields network compliance flags, and reads the same storefront a regulator would. A site full of dosing instructions and disease claims is a site an underwriter classifies as selling unapproved drugs to consumers. That classification is grounds for immediate action.

The sequence usually looks like this:

1. A monitoring sweep, a card-network alert, or a chargeback pattern surfaces your marketing claims.
2. The processor reclassifies your business from "research supply" to "unapproved pharmaceuticals."
3. Payouts pause while the account goes under review. Settled funds you were counting on stop arriving.
4. The account is terminated, and in the worst case the business is placed on the MATCH list, which makes opening a new merchant account elsewhere very hard.

The claim you wrote to lift conversion is the same claim the underwriter cites to shut you down. This is why marketing compliance is not a legal afterthought sitting in a different department from payments. It is a payments problem first. For the broader pattern of why these accounts collapse, read ./why-peptide-payments-get-shut-off.md, and for the specific outcome you most want to avoid, ./avoiding-match-list.md.

Where the line actually sits: a working test

You do not need a lawyer on retainer to sanity-check a piece of copy. You need one question applied honestly to every sentence, image, and tag on your funnel:

Does this state, imply, or invite a human to use the product?

If the answer is yes, you have crossed into human intended use and the RUO frame no longer protects you. Run the test against the parts of your funnel that founders forget:

• Product titles and category names
• Meta descriptions and SEO copy
• Ad creative, ad headlines, and landing-page hooks
• FAQ answers and chat-widget scripts
• Affiliate pages and influencer briefs
• Review sections and user-generated content
• Email flows and SMS sequences

The trap is that compliance teams clean the main product pages and leave the edges dirty. An affiliate's blog post, a year-old email, or a customer review with a dosing question and an on-brand reply can carry the same human-use intent as a headline. Regulators and underwriters read the whole property, not the homepage.

Marketing that converts inside the RUO frame

Staying compliant does not mean writing copy so bland nobody buys. It means selling the things that are genuinely true about a research-supply business, which turn out to be strong selling points to the audience that buys research compounds.

Sell purity and quality, not effects. Third-party testing, certificates of analysis, purity percentages, and lot transparency are claims you can fully substantiate and that serious buyers care about. "Independently tested to 99% purity, COA on every lot" outperforms a vague effect claim with the audience that matters.

Sell the research-supply experience. Fast shipping, cold-chain handling, reliable reconstitution-ready presentation, responsive support, and consistent lot quality are operational claims, not health claims. They are also exactly what repeat buyers reward.

Speak to the researcher, never to the patient. Frame the buyer as someone conducting laboratory study. Reference research applications generically and in the literature sense, not as a how-to for personal use. Keep the audience and the intent consistent across every page.

Let science be science. Citing published research on a compound is different from claiming your product delivers those outcomes to a buyer. Keep citations descriptive and in the third person. Never bridge from "studies observed X" to "you will experience X," which is the move that creates an implied claim.

Substantiate everything you say. The FTC standard is competent and reliable evidence. If you cannot point to the evidence behind a sentence, cut the sentence. This single habit removes most FTC exposure on its own.

For how these principles translate into a site that survives underwriting, work through ./peptide-website-compliance-checklist.md and ./age-gates-disclaimers-ruo-shield.md.

A note for telehealth and the GLP-1 category

If your business is genuinely clinical, a licensed-provider telehealth model prescribing compounded medications, the rules are different and in some ways more forgiving, because lawful prescribing is a legitimate human use under medical supervision. That model carries its own marketing discipline, especially around the incretin (GLP-1) category, where the FTC and FDA scrutiny is intense and where compounded-medication claims have hard limits.

The two models do not mix. A research-supply brand cannot borrow telehealth's human-use freedom, and a telehealth brand cannot borrow the RUO shield to dodge clinical oversight. Pick the model, build the marketing for that model, and keep them separate. For the telehealth side, see ./incretin-glp1-telehealth-processing.md and ./telehealth-recurring-billing-compliance.md.

How Holistic Payments approaches marketing risk

Holistic Payments underwrites RUO peptide and telehealth brands on our own Stripe Connect platform with four years of operating history. Compliance-first underwriting means we look at your marketing the way a regulator and a card network would, before either of them does. That is not a hurdle we put in front of approval. It is the work that keeps you processing after approval.

Where competitors approve a marginal site quickly and then drop it the moment monitoring flags a claim, our model is built to keep compliant merchants on stable rails. We can tell you which sentences create exposure, what the RUO frame requires across your whole funnel, and how to keep persuasion without inviting reclassification. Because Stripe handles KYC, onboarding stays fast and low-friction even though the compliance bar is high. And if you are migrating off a processor that just shut you down, we can move you over while you clean the marketing that caused the problem. For what that move looks like, read ./migrating-payment-processors.md.

We do not advise anyone to hide products, miscode an MCC, or cloak content from review. The opposite. The entire argument is that genuinely compliant marketing is the durable competitive advantage, because it is the one thing a processor cannot find a reason to terminate.

FAQ

Does research-use-only labeling protect me from FDA and FTC enforcement? Only when your marketing honors the label. RUO labeling removes human intended use from your product, which is the FDA's test for drug status. The moment your copy adds dosing, disease claims, or human-use signals back in, the label becomes evidence that you knew the product was not for consumption and marketed it anyway. The sticker and the marketing have to tell the same story.

Can I cite published peptide studies in my marketing? Yes, carefully. Describing what the literature observed, in the third person, is different from claiming your product delivers those outcomes to a buyer. Keep citations descriptive and never bridge from "studies observed X" to "you will get X." That bridge is what turns a citation into an implied claim the FTC can act on.

Why would my processor care about FTC or FDA risk before either agency acts? Because the processor owns the legal and brand risk through the card networks. Acquirers and networks monitor for unapproved-drug and deceptive-health-claim exposure and can pause payouts or terminate an account based on their own review, with no government letter required. The processor almost always moves faster than the regulator.

What is the single most dangerous element on a peptide site? Dosing instructions. "Take this much, this often" is an explicit instruction for human use, which converts an RUO vial into an unapproved drug faster than any other element. Remove all dosing language before anything else.

Can I market a research peptide as an alternative to a prescription medication? No. Comparing your compound to a named prescription medicine imports that medicine's human use into your product and creates an implied therapeutic claim. It is one of the clearest ways to trigger both agencies and your processor at once. Keep prescription compound names out of RUO marketing entirely.

Get approved on rails built to survive scrutiny

If your peptide or telehealth brand keeps getting approved and then shut off, the cause is usually upstream of payments: marketing claims that reclassify your product the moment anyone looks closely. Fix the marketing and you fix the durability. Holistic Payments brings compliance-first underwriting, deep RUO and telehealth expertise, peptide-friendly banking, and fair, transparent rolling reserves (typically 5 to 10 percent, held about 60 days and then re-evaluated) on a Stripe Connect platform with four years of operating history. We will read your funnel with you, tell you where the line is, and put you on rails built to survive review.

Apply at holisticpayments.io to get underwritten by a processor that wants you compliant and processing for the long run.